News | Colonoscopy Systems | April 15, 2019

Check-Cap Initiates U.S. Pilot Study of C-Scan for Colorectal Cancer Screening

Pilot study of preparation-free ingestible capsule will enroll up to 45 patients at average risk for polyps and colon cancer

Check-Cap Initiates U.S. Pilot Study of C-Scan for Colorectal Cancer Screening

April 15, 2019 — Check-Cap Ltd. has initiated its U.S. pilot study of the C-Scan system for prevention of colorectal cancer through detection of precancerous polyps, following Institutional Review Board (IRB) approval and full Investigational Device Exemption (IDE) application approval by the U.S. Food and Drug Administration (FDA). The first patients have ingested C-Scan, a preparation-free capsule, at the New York University School of Medicine.

"We are pleased to participate in this pilot study of C-Scan, a preparation-free capsule-based system for the prevention of colorectal cancer being tested in the U.S.," noted Seth A. Gross, M.D., gastroenterologist and associate professor of medicine, NYU Langone Health. "Unfortunately, colorectal cancer remains the second-leading cause of cancer death in the U.S. But we know that with the utilization of colorectal cancer screening, we can reduce the incidence and mortality rates related to this disease. The potential addition of a new screening option that is capsule-based and does not require a bowel prep offers the promise of increasing our screening rates. We are looking to the results of this study and the potential for an effective new screening option for the prevention and early detection of colorectal cancer."

The single-arm pilot study (NCT03735407) will enroll up to 45 subjects considered to be of average risk for polyps and colon cancer. The study is evaluating the safety, usability and subject compliance of the C-Scan system.

It is estimated that in 2018, there were approximately 881,000 deaths and more than 1.8 million new cases of colorectal cancer (CRC) worldwide. CRC typically begins as precancerous polyps or abnormal growths in the colon or rectum, which can be present for up to 10 years before developing into invasive cancer. As a result, screening for precancerous polyps is the most direct method for CRC prevention. Despite evidence that standard screening can prevent CRC, adherence remains low due to the required bowel preparation, invasiveness, and in some communities, limited access.

The C-Scan system utilizes an ultra-low dose X-ray capsule, an integrated positioning, control and recording system, as well as proprietary software to generate a 3-D map of the inner lining of the colon. C-Scan is non-invasive and requires no preparation or sedation, allowing the patient to continue their daily routine with no interruption as the capsule is propelled through the gastrointestinal tract by natural motility.

Read the article "Check-Cap Enrolls First Patient in C-Scan Colorectal Cancer Screening Clinical Trial"

For more information: www.check-cap.com

Related Content

The new X-ray scanner can provide detailed information about the internal makeup of rocks, which could be useful for archaeologists studying fossils or miners making decisions about which ore to use in their extraction facilities. Image courtesy of Joel Greenberg, Duke University

The new X-ray scanner can provide detailed information about the internal makeup of rocks, which could be useful for archaeologists studying fossils or miners making decisions about which ore to use in their extraction facilities. Image courtesy of Joel Greenberg, Duke University

News | X-Ray | June 10, 2021
June 10, 2021 — Engineers at Duke University have demonstrated a prot
Detection Technology, a global leader in X-ray detector solutions, has expanded its X-Scan T camera family to address a wide range of industrial inspection needs.
News | X-Ray | June 09, 2021
June 9, 2021 — Detection Technology, a global leader in...
The U.S. Food and Drug Administration (#FDA) approved #Aduhelm (#aducanumab) for the treatment of #Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.

Getty Images

News | PET Imaging | June 07, 2021
June 7, 2021 — The U.S.
Chest X-rays used in the COVID-Net study show differing infection extent and opacity in the lungs of COVID-19 patients. Image courtesy of University of Waterloo

Chest X-rays used in the COVID-Net study show differing infection extent and opacity in the lungs of COVID-19 patients. Image courtesy of University of Waterloo

News | Coronavirus (COVID-19) | June 03, 2021
June 3, 2021 — Artificial intelligence
Turner Imaging Systems, a developer of advanced X-ray imaging systems, announced the company has received its CE Mark for its Smart-C Mini C-Arm portable fluoroscopy x-ray imaging device.
News | Mobile C-Arms | June 01, 2021
June 1, 2021 — Turner Imaging Systems, a developer of advanced...
Feature | Coronavirus (COVID-19) | May 26, 2021 | By Dave Fornell, Editor
May 26, 2021 — There are increasing reports of persistent symptoms after a patient recovers from...
The KA X-ray technology gives doctors a clearer view of a patient's lungs by separating the bone structure (left) and soft tissue (right).

The KA X-ray technology gives doctors a clearer view of a patient's lungs by separating the bone structure (left) and soft tissue (right).

News | Digital Radiography (DR) | May 25, 2021
May 25, 2021 - KA Imaging has signed a distribution agreement in the U.S. with Alpha Imaging.
The experimental drug avasopasem manganese protects healthy tissue while enhancing radiation's capacity to kill cancerous tumor cells by converting superoxide to hydrogen peroxide. Image courtesy of Michael Story, Ph.D.

The experimental drug avasopasem manganese protects healthy tissue while enhancing radiation's capacity to kill cancerous tumor cells by converting superoxide to hydrogen peroxide. Image courtesy of Michael Story, Ph.D.

News | Radiation Therapy | May 21, 2021
May 21, 2021 — An experimental drug that has shown promise in protecting healthy tissue from collateral damage caused